Raging Biotech

The potential for synergistic benefits and the competitive edge offered by Omega's technology make it more likely for big pharma to partner with the company rather than go it alone in this dynamic and competitive space. Precision Medicine Powerhouse: Novo Nordisk Bets on Omega's Epigenetic Therapy Platform Novo Nordisk has entered into research collaborations with Omega Therapeutics to develop novel treatment approaches for cardiometabolic diseases, including obesity management. The collaboration will leverage Omega Therapeutics' OMEGA platform, which is designed to develop programmable epigenomic mRNA medicines, including epigenomic controllers. This partnership indicates Novo Nordisk's interest in the potential of Omega Therapeutics' platform and its application in addressing cardiometabolic diseases. Novo Nordisk's move aligns with a broader trend of big pharma companies embracing epigenomics as a promising frontier in drug development. With this new partner

Vivani Medical, Inc. (Nasdaq: VANI) has announced a securities purchase agreement with an institutional investor for 3,947,368 shares of common stock and warrants to purchase up to an aggregate of 3,947,368 shares of common stock at a purchase price of 3.80 per share. This direct offering, which is expected to generate approximately 15.0 million in gross proceeds before deducting placement agent fees and other expenses, demonstrates the confidence that this institutional investor has in Vivani's innovative approach to developing novel, long-term drug implants. It's important to note that this offering is not a dump of shares into the open market, but rather a targeted issuance to an institutional investor who recognizes the potential value of Vivani's technology. The fact that Maxim Group LLC is acting as the sole placement agent and ThinkEquity is acting as financial advisor to the Company further underscores the credibility of this offering. Moreover, the offering is bei